 | Up a level |
Kontopoulou, Konstantina; Nakas, Christos T.; Belai, Chrysoula; Papazisis, Georgios (2022). Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary? Journal of medical virology, 94(10), pp. 5056-5060. Wiley-Liss 10.1002/jmv.27954
Kontopoulou, Konstantina; Nakas, Christos T.; Papazisis, Georgios (2022). Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece. Vaccines, 10(6), p. 876. MDPI 10.3390/vaccines10060876
Kontopoulou, Konstantina; Nakas, Christos Theodore; Ainatzoglou, Alexandra; Ifantidou, Athina; Ntotsi, Paschalina; Katsioulis, Christos; Papazisis, Georgios (2021). Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study. Aging clinical and experimental research, 33(12), pp. 3385-3389. Springer 10.1007/s40520-021-01997-7
Kontopoulou, Konstantina; Ainatzoglou, Alexandra; Nakas, Christos T.; Ifantidou, Athina; Goudi, Georgia; Antoniadou, Eleni; Adamopoulos, Vasilios; Papadopoulos, Nikitas; Papazisis, Georgios (2021). Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive. Vaccine, 39(36), pp. 5078-5081. Elsevier 10.1016/j.vaccine.2021.07.065
Kontopoulou, Konstantina; Ainatzoglou, Alexandra; Ifantidou, Athina; Nakas, Christos T.; Gkounti, Georgia; Adamopoulos, Vasilios; Papadopoulos, Nikitas; Papazisis, Georgios (2021). Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers. Journal of medical microbiology, 70(8) SGM 10.1099/jmm.0.001387
